Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs

Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs

KKRX:950130
1,615.00
KRW
-26.00
(-1.58%)
-2,413.08EPS
97.78BMarket Cap
Access Bio, Inc. Shs Korean Deposit Receipt Repr. 1 shs
KRX:950130
(Korea Stock Exchange)

Recent

price

1,615.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
- -
- -
2,239.38
1,924.13
1,196.18
1,265.62
1,281.67
1,131.2
1,565.69
1,513.02
3,603.02
14,200.87
29,974.76
9,999.42
3,283.49
887.58
444.92
Revenue per Share
- -
- -
451
329
90.06
45
12
-249
-165
-618
1,428
5,333
10,051
-91
-10.15
-2,332
-2,388.06
Basic EPS, GAAP
- -
- -
-31
-82.91
-369.47
-135.64
-388.09
-430.09
-362.26
-136.1
738.48
3,637.1
10,155.93
-3,515
521.17
-879.62
-2,062.99
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
841.54
- -
- -
- -
Dividend per Share
- -
- -
1,313.89
1,851.33
2,241.3
2,380.96
2,186.38
1,676.62
1,421.89
749.18
2,351.59
8,049.82
18,199.04
17,276.64
18,483.97
15,841.05
16,208.47
Book Value per Share
- -
- -
1,146.15
1,673.51
2,002.78
2,076.32
1,818.28
1,308.11
1,031.55
594.92
2,297.08
8,001.56
18,155.74
17,241.06
18,465.96
15,834.82
16,184.07
Tangible Book Value per Share
20
20
17
24
27
28
25
26
26
28
34
36
34
35
34
35
35
Basic Weighted Avg Shares
- -
- -
36,998
45,840
32,305
35,583
32,486
29,465
40,239
43,059
121,797
505,112
1,033,863
348,643
112,463
31,255
15,549
Sales/Revenue/Turnover
- -
- -
23
24.86
7.28
0.02
-2.15
-23.27
-13.37
-18.67
56.41
51.5
45.42
6.29
-3.72
-202.48
-429.37
Operating Margin (%)
- -
- -
547
696
1,060
1,777
2,253
2,533
3,072
3,420
3,414
6,064
10,826
15,960
20,078
17,160
14,496
Depreciation Expense
- -
- -
7,451
7,838
2,432
1,265
304
-6,486
-4,241
-17,588
48,272
189,690
346,670
-3,173
-348
-82,118
-83,461
Net Income, GAAP
- -
- -
31.48
35.43
28.33
71.45
- -
- -
- -
- -
23.47
25.97
24.57
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
20.14
17.1
7.53
3.56
0.94
-22.01
-10.54
-40.85
39.63
37.55
33.53
-0.91
-0.31
-262.74
-536.74
Profit Margin (%)
- -
- -
11,492
35,146
45,008
43,680
55,775
18,057
17,307
8,169
42,308
189,940
519,440
374,416
459,840
408,405
395,692
Working Capital
- -
- -
251
212
183
156
28,926
18,475
24,167
22,864
12,431
12,008
62,442
59,714
45,906
24,577
25,249
LT Debt
- -
- -
21,707
50,197
68,584
76,882
69,661
54,090
43,415
27,900
86,681
290,047
626,098
587,141
652,405
558,489
571,291
Total Equity
- -
- -
- -
19.67
2.75
- -
- -
- -
- -
- -
51.07
88.38
76.91
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
21.72
4.99
2.8
- -
- -
- -
- -
50.17
77.63
65.61
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
21.8
4.4
2.04
0.5
-12.78
-10.42
-56.79
89.16
102.45
76.64
-0.53
-0.06
-13.6
-13.75
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
21,847
18,268
18,454
LT Borrowings
- -
- -
- -
LT Finance Leases
37,645
24,577
25,249
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
137,354
133,661
97,783

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
443,427
433,272
420,642
Cash, Cash Equivalents & STI
411,943
402,997
376,459
Accounts Receivable, Net
1,571
2,441
3,373
Inventories
18,002
10,718
11,473
Total Current Liabilities
30,025
24,866
24,950
Payables & Accruals
- -
- -
- -
ST Debt
21,847
18,268
18,454
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.44%
68.19%
-14.4%
Free Cash Flow
-58.2%
13.18%
-273.52%
Net Income, GAAP
2,130.91%
4,742.35%
23,526%
Sales/Revenue/Turnover
42.16%
42.63%
-72.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35,109
25,088
22,920
29,861
112,463
2025
21,707
1,375
3,556
5,228
31,255
2026
5,390
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
80
40
-135
2.64
-10.15
2025
-189
-300
-325
-1,534.57
-2,332
2026
-220
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Access Bio Inc (950130.KS) develops, manufactures and markets in vitro diagnostic tests for infectious diseases worldwide. The company offers rapid diagnostic tests including CareStart Malaria, CareStart Dengue Combo, CareStart G6PD RDT, CareStart Scrub Typhus IgM, CareStart COVID-19 Antigen and serology tests for SARS-CoV-2 detection; biosensors such as CareStart G6PD Biosensor and analyzers for measuring biological samples; molecular diagnostic products like CareStart HPV, CareStart CAH and PCR-based solutions for genome and proteome analysis. Founded in 2001 and headquartered in Somerset, New Jersey, Access Bio Inc operates manufacturing facilities in the US, South Korea and Ethiopia, serving international public health agencies, medical facilities and organizations focused on diseases including malaria, HIV, HPV, influenza, dengue and COVID-19. In recent developments, the company received KRW 9.49 billion in funding from Lion's Head Global Partners in support of its operations; expanded its COVID-19 portfolio with FDA Emergency Use Authorizations for point-of-care antigen, serology and molecular tests during the pandemic, including distribution of over 300 million home test kits; and built the largest rapid diagnostic test facility in the US post-COVID.